Antibody-drug conjugate (ADC) technologies enable the targeted delivery of potent cytotoxic payloads to cancer cells via monoclonal antibodies. Successive generations of ADC platforms have improved homogeneity, stability, and therapeutic index through advances in conjugation chemistry, linker design, and payload selection. Third-generation technologies currently dominate, while next-generation approaches are expanding rapidly.At the center of platform innovation is the ADC Technology Market, which is projected to grow significantly through the forecast period as developers seek more efficient and safer conjugation methods. Chemical conjugation remains the most widely used approach, with chemoenzymatic and enzymatic methods gaining traction. North America currently leads the market, while Asia-Pacific is expected to show the fastest growth.
Read More: https://www.rootsanalysis.com/reports/adc-technology-market.html